内皮生长因子受体突变阳性的非小细胞肺癌拉穆单抗诱发腹水：两个病例报告。

IF 0.8 Q4 RESPIRATORY SYSTEM

Respirology Case Reports Pub Date : 2024-10-14 eCollection Date: 2024-10-01 DOI:10.1002/rcr2.70046

Keisuke Shiraha, Tomoki Tamura, Taisaku Koyanagi, Takahiro Umeno, Kazuya Nishii, Shoichi Kuyama

{"title":"内皮生长因子受体突变阳性的非小细胞肺癌拉穆单抗诱发腹水：两个病例报告。","authors":"Keisuke Shiraha, Tomoki Tamura, Taisaku Koyanagi, Takahiro Umeno, Kazuya Nishii, Shoichi Kuyama","doi":"10.1002/rcr2.70046","DOIUrl":null,"url":null,"abstract":"Ramucirumab (RAM) has been approved for the treatment of non-small cell lung cancer (NSCLC). Here, we report two cases of RAM-induced ascites with epidermal growth factor receptor-mutant NSCLC. Patient 1, a 72-year-old man, developed ascites 20 months after erlotinib (ERL) and RAM administration, which resolved after their discontinuation and performing paracentesis. Patient 2, an 83-year-old woman, developed ascites 9 months after ERL and RAM administration, which resolved after RAM discontinuation and furosemide administration. Ramucirumab administration can cause ascites due to increased hepatic sinusoidal pressure. Clinicians should be aware of RAM-induced ascites in patients with NSCLC and should appropriately manage it.","PeriodicalId":45846,"journal":{"name":"Respirology Case Reports","volume":"12 10","pages":"e70046"},"PeriodicalIF":0.8000,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11473188/pdf/","citationCount":"0","resultStr":"{\"title\":\"Ramucirumab-induced ascites with endothelial growth factor receptor mutation-positive non-small cell lung cancer: Two case reports.\",\"authors\":\"Keisuke Shiraha, Tomoki Tamura, Taisaku Koyanagi, Takahiro Umeno, Kazuya Nishii, Shoichi Kuyama\",\"doi\":\"10.1002/rcr2.70046\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Ramucirumab (RAM) has been approved for the treatment of non-small cell lung cancer (NSCLC). Here, we report two cases of RAM-induced ascites with epidermal growth factor receptor-mutant NSCLC. Patient 1, a 72-year-old man, developed ascites 20 months after erlotinib (ERL) and RAM administration, which resolved after their discontinuation and performing paracentesis. Patient 2, an 83-year-old woman, developed ascites 9 months after ERL and RAM administration, which resolved after RAM discontinuation and furosemide administration. Ramucirumab administration can cause ascites due to increased hepatic sinusoidal pressure. Clinicians should be aware of RAM-induced ascites in patients with NSCLC and should appropriately manage it.\",\"PeriodicalId\":45846,\"journal\":{\"name\":\"Respirology Case Reports\",\"volume\":\"12 10\",\"pages\":\"e70046\"},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2024-10-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11473188/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Respirology Case Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/rcr2.70046\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/10/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respirology Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/rcr2.70046","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 0

摘要

雷莫芦单抗（RAM）已被批准用于治疗非小细胞肺癌（NSCLC）。在此，我们报告了两例由雷姆单抗诱发的表皮生长因子受体突变型 NSCLC 腹水病例。患者 1 是一名 72 岁的男性，在服用厄洛替尼（ERL）和 RAM 20 个月后出现腹水，停药并进行腹腔穿刺后腹水消退。患者 2 是一名 83 岁的女性，在服用厄洛替尼和雷莫芦单抗 9 个月后出现腹水，在停用雷莫芦单抗并服用呋塞米后腹水消退。由于肝窦压力升高，使用雷莫芦单抗可导致腹水。临床医生应注意 RAM 引起的 NSCLC 患者腹水，并进行适当处理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Ramucirumab-induced ascites with endothelial growth factor receptor mutation-positive non-small cell lung cancer: Two case reports.

Ramucirumab (RAM) has been approved for the treatment of non-small cell lung cancer (NSCLC). Here, we report two cases of RAM-induced ascites with epidermal growth factor receptor-mutant NSCLC. Patient 1, a 72-year-old man, developed ascites 20 months after erlotinib (ERL) and RAM administration, which resolved after their discontinuation and performing paracentesis. Patient 2, an 83-year-old woman, developed ascites 9 months after ERL and RAM administration, which resolved after RAM discontinuation and furosemide administration. Ramucirumab administration can cause ascites due to increased hepatic sinusoidal pressure. Clinicians should be aware of RAM-induced ascites in patients with NSCLC and should appropriately manage it.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Respirology Case Reports RESPIRATORY SYSTEM-

CiteScore

1.40

自引率

0.00%

发文量

178

审稿时长

8 weeks

期刊介绍： Respirology Case Reports is an open-access online journal dedicated to the publication of original clinical case reports, case series, clinical images and clinical videos in all fields of respiratory medicine. The Journal encourages the international exchange between clinicians and researchers of experiences in diagnosing and treating uncommon diseases or diseases with unusual presentations. All manuscripts are peer-reviewed through a streamlined process that aims at providing a rapid turnaround time from submission to publication.